Wikidata entity: Q423467
C₃₈H₅₂N₆O₇ (P274)
Quantities
| P4250 | defined daily dose | 0.3 |
| P2067 | mass | 704.39 |
| P3780 | active ingredient in | ... | Q29006436 (Reyataz) | Reyataz |
| P233 | canonical SMILES | String | CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC | ??? |
| P972 | catalog | ... | Q90481889 (CAS COVID-19 Anti-Viral Candidate Compounds) | CAS COVID-19 Anti-Viral Candidate Compounds |
| P373 | Commons category | String | Atazanavir | ??? |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2017 | isomeric SMILES | String | CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC | ??? |
| P3493 | legal status (medicine) | ... | Q879952 (boxed warning) | boxed warning |
| P8026 | LiverTox likelihood score | ... | Q83284515 (LiverTox toxicity likelihood category D) | LiverTox toxicity likelihood category D |
| P3489 | pregnancy category | ... | Q3679233 (Australian pregnancy category B2) | Australian pregnancy category B2 |
| P3489 | pregnancy category | ... | Q28123616 (US pregnancy category B) | US pregnancy category B |
| P769 | significant drug interaction | ... | Q3515 ((RS)-rabeprazole) | (RS)-rabeprazole |
| P769 | significant drug interaction | ... | Q118551 (clarithromycin) | clarithromycin |
| P769 | significant drug interaction | ... | Q179996 ((RS)-methadone) | (RS)-methadone |
| P769 | significant drug interaction | ... | Q254296 (lansoprazole) | lansoprazole |
| P769 | significant drug interaction | ... | Q286846 (pantoprazole) | pantoprazole |
| P769 | significant drug interaction | ... | Q407721 (buprenorphine) | buprenorphine |
| P769 | significant drug interaction | ... | Q407883 (ketoconazole) | ketoconazole |
| P769 | significant drug interaction | ... | Q410412 (carbamazepin) | carbamazepin |
| P769 | significant drug interaction | ... | Q422210 (omeprazole) | omeprazole |
| P769 | significant drug interaction | ... | Q422645 (efavirenz) | efavirenz |
| P769 | significant drug interaction | ... | Q411648 (tacrolimus) | tacrolimus |
| P769 | significant drug interaction | ... | Q415159 (rosuvastatin) | rosuvastatin |
| P769 | significant drug interaction | ... | Q419769 (bosentan) | bosentan |
| P769 | significant drug interaction | ... | Q422652 (rifampicin) | rifampicin |
| P769 | significant drug interaction | ... | Q668093 (atorvastatin) | atorvastatin |
| P769 | significant drug interaction | ... | Q113368879 (rac-warfarin) | rac-warfarin |
| P769 | significant drug interaction | ... | Q1135705 (rifabutin) | rifabutin |
| P769 | significant drug interaction | ... | Q3935297 (rifapentine) | rifapentine |
| P769 | significant drug interaction | ... | Q27132753 (tenofovir disoproxil) | tenofovir disoproxil |
| P3364 | stereoisomer of | ... | Q82535664 (Methyl [(5S,10R,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-{[4-(pyridin-2-yl)phenyl]methyl}-2-oxa-4,7,8,12-tetraazahexadecan-14-yl]carbamate (non-preferred name)) | Methyl [(5S,10R,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-{[4-(pyridin-2-yl)phenyl]methyl}-2-oxa-4,7,8,12-tetraazahexadecan-14-yl]carbamate (non-preferred name) |
| P279 | subclass of | ... | Q126612563 (Deuterated Atazanivir-D3-3) | Deuterated Atazanivir-D3-3 |
| P2868 | subject has role | ... | Q35456 (essential medicine) | essential medicine |
| P2868 | subject has role | ... | Q846227 (antiviral drug) | antiviral drug |
| P2868 | subject has role | ... | Q804539 (bactericide) | bactericide |
| P2868 | subject has role | ... | Q55761529 (protease inhibitor) | protease inhibitor |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | atazanavir | ??? |
Why not click here or view trends?
log id: 1961117